South Africa is one of only six countries to ever meet their “fair share target” for funding tuberculosis (TB) research, according to a new report. In absolute terms however, South Africa’s contribution is small change compared to investments into TB research made by the top two contributors, the United States government and the Bill and Melinda Gates Foundation. Catherine Tomlinson unpacks what the report tells us about investment in TB research in South Africa.
A massive and much-anticipated phase 3 trial of an experimental tuberculosis (TB) vaccine is set to proceed after funding for it has been secured from two large philanthropies. If the trial’s findings are positive, the vaccine is likely to become the first new TB vaccine in over a hundred years to be widely used. Marcus Low reports.
The current treatment for drug-susceptible tuberculosis (TB) used in South Africa last for six months, effectively cures TB and is dirt cheap. Two studies in recent years have shown that TB can be cured in four or in some cases even two months, but price and other complications make these treatments tricky to implement. At a conference in Seattle last week, a major trial of an alternative four-month treatment reported disappointing findings. Elri Voigt unpacks the latest findings and asks what the prospects now are for shortening TB treatment.
Some cases of tuberculosis (TB) can be successfully treated in as little as two months – a third of the current standard of six months. This is according to early findings from the landmark TRUNCATE TB trial presented at last week’s Union World Conference on Lung Health. Elri Voigt reports.
The rollout of new TB prevention medicines in South Africa has progressed slower than expected and new TB prevention guidelines have been delayed. But, reports Catherine Tomlinson, new guidelines should soon be approved and things appear to be falling into place for a faster rollout of the new medicines.
While there are nine experimental tuberculosis (TB) vaccines in advanced trials, the vaccine pipeline beyond those nine prospects is relatively depleted. Adele Baleta reports on this and much more from the virtual Global TB Vaccine Forum held last week.
After various delays and setbacks, a new, less toxic, short-course tuberculosis preventive therapy called 3HP is finally being launched in six districts in South Africa. Tiyese Jeranji reports.
A new four-month treatment course for drug-sensitive tuberculosis (the most common form of TB by far) is as safe and effective as the current six-month treatment course that has been in use since the 1980s, according to findings from a large new study. Amy Green reports.
In recent months, the world has seen unprecedented investment in new vaccines. Yet, while a COVID-19 vaccine proven to be safe and effective may be less than a year away, a new tuberculosis vaccine might only be ready to be rolled out in a decade, despite a massive head start over COVID-19. Amy Green takes a closer look at the race for a new vaccine for the world’s top infectious disease killer.